🔬 Bone Profile

A group of blood tests (Calcium, Albumin, Phosphate, ALP) used to assess calcium homeostasis and bone turnover.

Indicated in the investigation of bone pain, pathological or fragility fractures, and suspected hypercalcaemia (presenting with 'stones, moans, groans, and psychic overtones'). It is used to monitor patients with known malignancy (e.g., breast, prostate, lung) for bone metastases. It is also required for monitoring patients on vitamin D replacement, those with renal failure, or those with primary hyperparathyroidism.

Venous blood sample collected in a plain or gel-separator tube (usually a gold or red top). The laboratory measures serum calcium, albumin, phosphate, and alkaline phosphatase (ALP). The 'adjusted' or 'corrected' calcium is then calculated based on the albumin level to provide an estimate of the physiologically active ionised calcium, as much of the circulating calcium is protein-bound.

Normal results show adjusted calcium, phosphate, and alkaline phosphatase within their respective laboratory reference ranges. Normal albumin levels ensure that total calcium measurements are representative. In a healthy adult, these values should remain relatively stable due to tight homeostatic control by PTH and Vitamin D.

Interpretation requires looking at the pattern of all three markers. A raised ALP with normal calcium and phosphate is classic for Paget’s disease of bone. In Vitamin D deficiency (osteomalacia), calcium and phosphate are often low or low-normal, while ALP and PTH are raised. In primary hyperparathyroidism, calcium is high and phosphate is low, whereas in secondary hyperparathyroidism (usually due to CKD), calcium is low-normal and phosphate is high.

Abnormalities include hypercalcaemia with low phosphate (often seen in primary hyperparathyroidism) or hypercalcaemia with high phosphate (suggestive of bone metastases or vitamin D toxicity). Hypocalcaemia with high phosphate is typical of chronic kidney disease (CKD) or hypoparathyroidism. Raised ALP is seen in Paget’s disease, bone metastases, or during fracture healing; if isolated, it requires differentiation from liver pathology. Low albumin will lower the 'total' calcium level, necessitating the use of 'adjusted' calcium.

The bone profile is central to the investigation of metabolic bone diseases (osteoporosis, osteomalacia), unexplained bone pain, and suspected malignancy. It is a vital screen for patients with fragility fractures or those starting medications that affect calcium metabolism (e.g., bisphosphonates). Furthermore, it helps monitor patients with CKD, where mineral bone disorder (CKD-MBD) is a common and serious complication.

A common pitfall is failing to correct for albumin, leading to a false diagnosis of hypocalcaemia in malnourished or unwell patients. Another is ignoring a raised ALP in an elderly patient, assuming it is 'just age,' when it may indicate Paget's disease or occult malignancy. Contamination of the sample with EDTA (from a FBC bottle) can cause profoundly low calcium and high potassium readings.

The bone profile does not include Vitamin D or Parathyroid Hormone (PTH) levels, which are often needed to fully interpret the results. ALP is not specific to bone; it is also found in the biliary tree, so a raised ALP requires correlation with other LFTs (like GGT) to confirm its origin. Serum calcium measurements reflect only a tiny fraction of total body calcium stores.

Always use the 'adjusted calcium' for clinical decisions. Remember that ALP can be physiological (e.g., in growing children or during the third trimester of pregnancy). In the context of malignancy, hypercalcaemia is an oncological emergency.